Get the Stockscreener App
13.41
1.82%
0.24
After Hours:
13.41
Design Therapeutics Inc stock is traded at $13.41, with a volume of 677.23K.
It is up +1.82% in the last 24 hours and up +19.41% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
See More
Previous Close:
$13.17
Open:
$13.34
24h Volume:
677.23K
Relative Volume:
2.02
Market Cap:
$837.55M
Revenue:
-
Net Income/Loss:
$-69.71M
P/E Ratio:
-11.24
EPS:
-1.1935
Net Cash Flow:
$-54.12M
1W Performance:
+4.68%
1M Performance:
+19.41%
6M Performance:
+104.73%
1Y Performance:
+207.57%
1-Day Range:
$13.19
$13.78
1-Week Range:
$12.95
$17.25
52-Week Range:
$3.105
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
13.41 | 822.56M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | Jefferies | Buy |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Initiated | Craig Hallum | Buy |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-20-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Scott Coop
Design Therapeutics Set For Multiple Clinical Trial Catalysts In H2 2026 - RTTNews
Oppenheimer Raises Price Target on Design Therapeutics to $21 From $18, Keeps Outperform Rating - marketscreener.com
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96 - MSN
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DSGN) 2026-04-30 - Seeking Alpha
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Transcript : Design Therapeutics, Inc., Q1 2026 Earnings Call, Apr 28, 2026 - marketscreener.com
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High Following Earnings Beat - MarketBeat
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings - MSN
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H - Investing.com Australia
Design Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations - Investing.com India
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
Design Therapeutics 1Q Loss/Shr 29c >DSGN - Moomoo
Design Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Design Therapeutics (NASDAQ: DSGN) Q1 loss, $223M cash and GeneTAC pipeline updates - Stock Titan
Design Therapeutics Reports Q1 2026 Results and Pipeline Progress - TipRanks
Design Therapeutics (NASDAQ:DSGN) Posts Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates - The Manila Times
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cash runway into 2029 as Design Therapeutics (NASDAQ: DSGN) advances trials - Stock Titan
$222.8M gives Design Therapeutics funding into 2029 as trials advance - Stock Titan
This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design. - Barron's
Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines - PR Newswire
Friedreich's Ataxia Pipeline Enters a Transformative Era with - openPR.com
Friedreich’s Ataxia Pipeline Enters a Transformative Era with 20+ Therapies and Strong Clinical Momentum from Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics | DelveInsight - Barchart
Design Therapeutics (DSGN) details 2026 annual meeting, director vote and auditor ratification - Stock Titan
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighStill a Buy? - MarketBeat
Episodic Ataxia Treatment Market Overview, Current Trends, and Key Player Analysis - openPR.com
Design Thera (DSGN) Stock Continuous Quote (Smart Money Flows) 2026-04-15Top Analyst Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month HighShould You Buy? - MarketBeat
Aug Movers: Can Design Therapeutics Inc expand its profit margins2026 Breakouts & Technical Entry and Exit Alerts - baoquankhu1.vn
We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth - Yahoo Finance
FOMO Trade: Can Design Therapeutics Inc navigate macro headwinds2026 Price Action Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Astellas Licenses Dyno Therapeutics’ AI-Designed AAV Capsid, Advancing Gene Delivery for Muscle Disorders - BioPharm International
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings (XLV:NYSEARCA) - Seeking Alpha
US Market Wrap: What is the long term forecast for Design Therapeutics Inc stock2026 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
Is Design Thera (DSGN) Stock at a Peak | Price at $12.50, Down 1.34%Growth Picks - Cổng thông tin điện tử Tỉnh Sơn La
DSGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design - Business Wire
PTCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Design Therapeutics (NASDAQ:DSGN) Trading Up 6.8%Still a Buy? - MarketBeat
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):